Skip to main content

Table 2 Laboratory characteristics before and after treatment with platelet-rich plasma (PRP) in for POSEIDON groups

From: Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: A retrospective study according to the POSEIDON criteria

Variables

POSEIDON 1

Median ± IQR

POSEIDON 2

Median ± IQR

POSEIDON 3

Median ± IQR

POSEIDON 4

Median ± IQR

P-value

Age (years)

32.00 ± 3.00

37.00 ± 8.00

33.00 ± 2.00

40.00 ± 5.00

 < 0.001

Poor responder (%)

2/7 (28.6%)

8/17 (47.1%)

12/16 (75%)

47/56 (83.9%)

0.002

Number of previous punctures

3 ± 2

3 ± 1

2.5 ± 1

2.00 ± 2.00

0.755

LH (IU/L)

Before PRP

1.87 ± 1.50

2.35 ± 2.82

2.51 ± 1.30

3.02 ± 1.75

0.160

After PRP

2.08 ± 1.43

2.98 ± 1.68

2.82 ± 2.20

3.05 ± 2.29

0.198

FSH (IU/mL)

Before PRP

4.27 ± 1.73

5.79 ± 2.65

6.08 ± 5.19

6.66 ± 5.11

0.054

After PRP

5.15 ± 1.63

5.60 ± 3.20

6.85 ± 4.23

7.21 ± 4.04

0.028

Estradiol (pg/mL)

Before PRP

31.00 ± 55.9

46.00 ± 16.65

57.15 ± 40.10

51.60 ± 34.10

0.576

After PRP

55.80 ± 20.30

51.70 ± 23.30

62.00 ± 45.68

45.00 ± 33.38

0.342

AMH (ng/mL)

Before PRP

1.75 ± 2.07

1.68 ± 0.98

0.6 ± 0.45

0.46 ± 0.51

 < 0.001

After PRP

1.85 ± 2.56

1.53 ± 1.03 *

0.64 ± 0.68

0.50 ± 0.56

 < 0.001

  1. IQR Interquartile range, LH Luteinizing hormone, FSH Follicle-stimulating hormone, AMH Anti-Mullerian hormone
  2. *: p-value < 0.05, **: p-value < 0.01, and ***: p-value < 0.001 all compare to the before level